DDInter624 DDInter484
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.[A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186]
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dasatinib
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Efavirenz {u} (Compound) downregulates {v} (Gene) PFN1
PFN1 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Efavirenz {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Dasatinib
Efavirenz {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) covaries with {v} (Gene) FMO3
FMO3 {u} (Gene) is bound by {v} (Compound) Dasatinib
Efavirenz {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Almotriptan
Almotriptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Dasatinib
Efavirenz {u} (Compound) downregulates {v} (Gene) PFN1
PFN1 {u} (Gene) is regulated by {v} (Gene) ABL1
ABL1 {u} (Gene) is bound by {v} (Compound) Dasatinib
Efavirenz {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dasatinib
Efavirenz {u} (Compound) causes {v} (Side Effect) Tachycardia
Tachycardia {u} (Side Effect) is caused by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dasatinib
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Dasatinib (Compound)
Efavirenz (Compound) downregulates PFN1 (Gene) and PFN1 (Gene) is downregulated by Dasatinib (Compound)
Efavirenz (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound)
Efavirenz (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) covaries with FMO3 (Gene) and FMO3 (Gene) is bound by Dasatinib (Compound)
Efavirenz (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Almotriptan (Compound) and Almotriptan may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Efavirenz (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Dasatinib (Compound)
Efavirenz (Compound) downregulates PFN1 (Gene) and PFN1 (Gene) is regulated by ABL1 (Gene) and ABL1 (Gene) is bound by Dasatinib (Compound)
Efavirenz (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Dasatinib
Efavirenz (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Dasatinib